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Objectives The aim of this study was to compare outcomes after transfemoral transcatheter aortic valve implantation with
the Medtronic CoreValve (MCV) versus the Edwards SAPIEN/SAPIEN XT transcatheter heart valve (ESV) for severe
aortic stenosis.
Background No large matched comparison study has been conducted so far evaluating both commercially available devices.
Methods The data from databases of 4 experienced European centers were pooled and analyzed. Due to differences in
baseline clinical characteristics, propensity score matching was performed. Study objectives were Valve Aca-
demic Research Consortium outcomes at 30 days and 1 year.
Results In total, 793 patients were included: 453 (57.1%) treated with the MCV and 340 (42.9%) with the ESV. After pro-
pensity matching, 204 patients were identified in each group. At 30 days, there were no differences in all-cause
mortality (MCV, 8.8% vs. ESV, 6.4%; hazard ratio [HR]: 1.422; 95% confidence interval [CI]: 0.677 to 2.984;
p  0.352), cardiovascular mortality (MCV, 6.9% vs. ESV, 6.4%; HR: 1.083; 95% CI: 0.496 to 2.364; p  0.842),
myocardial infarction (MCV, 0.5% vs. ESV, 1.5%; HR: 0.330; 95% CI: 0.034 to 3.200; p  0.339), stroke (MCV,
2.9% vs. ESV, 1.0%; HR: 3.061; 95% CI: 0.610 to 15.346; p  0.174), or device success (MCV, 95.6% vs. ESV,
96.6%; HR: 0.770; 95% CI: 0.281 to 2.108; p  0.611). Additionally, there were no differences in major vascu-
lar complications (MCV, 9.3% vs. ESV, 12.3%; HR: 0.735; 95% CI: 0.391 to 1.382; p  0.340) or life-threatening
bleeding (MCV, 13.7% vs. ESV, 8.8%; HR: 1.644; 95% CI: 0.878 to 3.077; p  0.120). MCV was associated with
more permanent pacemakers (22.5% vs. 5.9%; HR: 4.634; 95% CI: 2.373 to 9.050; p  0.001). At 1 year, there
were no differences in all-cause (MCV, 16.2% vs. ESV, 12.3%; HR: 1.374; 95% CI: 0.785 to 2.407; p  0.266) or
cardiovascular (MCV, 8.3% vs. ESV, 7.4%; HR: 1.145; 95% CI: 0.556 to 12.361; p  0.713) mortality.
Conclusions No differences between the 2 commercially available transfemoral transcatheter aortic valve implantation
devices were observed at the adjusted analysis in Valve Academic Research Consortium outcomes except
for the need for permanent pacemakers with the MCV. (J Am Coll Cardiol 2013;61:830–6) © 2013 by the
American College of Cardiology Foundation
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012, accepted November 20, 2012.For high-risk patients with severe symptomatic aortic ste-
nosis, transcatheter aortic valve implantation (TAVI) has
emerged as an effective alternative (1–5). Since its intro-
duction, 2 devices have been in widespread use through-
out Europe. The first is the Medtronic CoreValve
(MCV) (Medtronic Inc., Minneapolis, Minnesota), a
nitinol self-expandable porcine pericardial tissue valve.
The other is the balloon-expandable Edwards SAPIEN/
SAPIEN XT transcatheter heart valve (ESV) (Edwards
Lifesciences, Irvine, California), composed initially of
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February 26, 2013:830–6 SAPIEN Versus CoreValvestainless steel and now of a cobalt chromium frame with
bovine pericardial leaflets.
Currently, a substantial body of data has been published
regarding outcomes following TAVI (1–8). However, so far,
no large comparison has been performed to assess differ-
ences between currently available valve types. The aim of
this multicenter collaborative registry was therefore to com-
pare 30-day and 1-year Valve Academic Research Consortium
(VARC) outcomes after transfemoral (TF) TAVI with MCV
versus ESV.
Methods
Patients. The PRAGMATIC Plus (Pooled-RotterdAm-
MilAno-Toulouse In Collaboration) initiative is a collabo-
ration of 4 European institutions with established TAVI
experience. The baseline characteristics and clinical out-
comes from a series of 944 patients who underwent TAVI
were collected since the introduction of the respective local
TAVI programs until July 2011: 1) San Raffaele Scientific
Institute, Milan, Italy (N  330); 2) Clinique Pasteur,
oulouse, France (N  224); 3) Thoraxcenter, Erasmus
edical Center, Rotterdam, the Netherlands (N  206);
nd 4) Hôpital Rangueil, Toulouse, France (N  184).
fter the VARC publication, clinical outcomes were adju-
icated, and all data pooled in a dedicated database.
Patient eligibility for TAVI at each center was described
reviously (9–11).
rocedures. Patients were included in this analysis if femoral
ccess was used. Both TAVI devices, commercially available at
he onset of the study, were used: the 18-F sheath–compatible
CV (except 5 cases with the 21-F device) and the ESV,
sing 22-/24-F sheaths until mid 2010 when the Novaflex
elivery catheter and the ESV-XT downgrading to 18-/19-F
evice was introduced. Sheath size was entered in the propen-
ity matching as a dichotomous variable, thus, excluding the
nitial devices in the adjusted analysis. Valve choice was at
perator discretion.
tudy endpoints. The study endpoints were defined ac-
ording to VARC (12). Residual aortic regurgitation (AR)
as evaluated by either transthoracic or transesophageal
chocardiography at all centers.
All patients provided written informed consent for the
rocedure and data collection according to the policy of each
ospital.
tatistical analysis. The analysis was performed according
o valve type. Continuous variables are expressed as mean 
D and analyzed with the Student t test or Wilcoxon rank
um test depending on the variable distribution. Categorical
ariables were compared with the chi-square test with Yates
orrection for continuity or the Fisher exact test. Because of
he nonrandomized nature of the study, to reduce treatment
election bias and potential confounding, we performed
igorous adjustment for significant differences in baseline
haracteristics with propensity-score matching. The score Eas calculated by performing a
ultiparsimonious multivariable
ogistic regression with valve type
s the dependent variable. The
ollowing covariants were se-
ected: age, sex, body mass index,
ogistic EuroSCORE (European
ystem for Cardiac Operative
isk Evaluation), Society of
horacic Surgeons score, previ-
us MI, coronary artery bypass
raft, or percutaneous coronary
ntervention, coronary artery dis-
ase, hypertension, chronic ob-
tructive pulmonary disease, dia-
etes mellitus, peripheral vascular
isease, chronic kidney disease,
erebrovascular disease, ejection
raction 35%, aortic annulus
iameter, and sheath size. The
-statistic for the propensity score model was 0.67, and the
osmer-Lemeshow goodness-of-fit was 0.33, confirming
ood calibration. To identify matched pairs, we used the
ollowing algorithm: 1:1 optimal match with a 0.01
aliper and no replacement. Clinical outcomes in the
atched population were analyzed with Cox proportional
azards regression stratified on matched pairs. Multivariable
ox proportional hazards regression modeling was per-
ormed to determine the independent predictors of study
bjectives with purposeful selection of covariates. Variables
ssociated at univariate analysis (all with a p value0.1) and
hose judged to be of clinical importance were eligible for
nclusion into the multivariable model-building process.
he goodness-of-fit of the Cox multivariable model was
ssessed with the Grønnesby-Borgan-May test. Results are
eported as hazard ratio (HR) with associated 95% confi-
ence interval (CI) and p value. Survival was recorded by
aplan-Meier analysis with the log-rank method used for
omparison. All statistical analyses were performed with
TATA (version 9.0, StataCorp, College Station, Texas). A
value of 0.05 was considered statistically significant.
esults
verall, 793 patients were treated with a TF access strategy:
53 (57.1%) with an MCV and 340 (42.9%) with an ESV.
aseline characteristics of the overall population are re-
orted in Table 1.
nadjusted VARCoutcomes in the overall population. At 30
ays, 34 patients (7.5%) died after receiving an MCV
ompared with 17 (5.0%) after receiving an ESV; cardio-
ascular death was, respectively, 28 (6.2%) and 17 (5.0%).
nline supplementary Table 1 shows predictors of mortal-
ty. Major stroke occurred in 16 MCV (3.5%) and 5 (1.5%)
Abbreviations
and Acronyms
AR  aortic regurgitation
CI  confidence interval
ESV  Edwards SAPIEN/
SAPIEN XT transcatheter
heart valve
HR  hazard ratio
MCV  Medtronic
CoreValve
MI  myocardial infarction
PPM  permanent
pacemaker
TAVI  transcatheter aortic
valve implantation
TF  transfemoral
VARC  Valve Academic
Research ConsortiumSV patients. Patients who had a stroke more frequently
Hp
E
l
P
o
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SAPIEN Versus CoreValve February 26, 2013:830–6had valve embolization or required a second valve (Online
Table 2).
Five patients (1.1%) with an MCV and 1 (0.3%) with an
ESV had a periprocedural MI. Coronary obstruction oc-
curred in only 1 patient in each group. Valve embolization
occurred in 30 MCV patients (6.6%) and in no ESV
patients, and there was a need for a second valve in 20 MCV
Baseline Characteristics of the Overall PopulationTable 1 Baseline Characteristics of the Overall Population
MCV (n  453) ESV (n  340) p Value
Age, yrs 80.9 6.7 81.6 7.3 0.125
Male 251 (55.4) 168 (49.4) 0.094
NYHA functional class III/IV 373 (82.3) 273 (80.8) 0.572
Logistic EuroSCORE 21.4 12.6 23.0 13.8 0.089
STS score 8.1 6.2 8.9 6.5 0.066
Previous stroke 75 (16.6) 46 (13.5) 0.241
Previous MI 88 (19.4) 41 (12.1) 0.005
Previous CABG 108 (23.8) 59 (17.4) 0.027
Previous PCI 128 (28.3) 101 (29.7) 0.656
Diabetes mellitus 129 (28.5) 94 (27.6) 0.797
Hypertension 292 (64.5) 244 (71.8) 0.030
GFR 60 ml/min 267 (58.9) 217 (64.2) 0.133
COPD 147 (32.5) 110 (32.4) 0.977
PVD 75 (16.6) 65 (19.3) 0.327
Annulus, mm 23.5 2.3 22.7 1.8 0.001
AVA, mm2 0.7 0.2 0.7 0.2 0.822
LVEF 35% 80 (17.7) 59 (17.4) 0.910
Values are n (%) or mean  SD.
AVA  aortic valve area; CABG  coronary artery bypass graft; COPD  chronic obstructive
ulmonary disease; ESV  Edwards SAPIEN/SAPIEN XT transcatheter heart valve; EuroSCORE 
uropean System for Cardiac Operative Risk Evaluation; GFR  glomerular filtration rate; LVEF 
eft ventricular ejection fraction; MCVMedtronic CoreValve; NYHA New York Heart Association;
CI percutaneous coronary intervention; PVD peripheral vascular disease; STS score Society
f Thoracic Surgeons predicted risk of mortality score.
Figure 1 Freedom From All Cause and Cardiac Mortality Accor
Freedom from all-cause (A) and cardiovascular (B) mortality at 1 year according to
regurgitation (AR). The green line represents no/trace AR, the blue line mild AR, a(4.4%) versus ESV 2 (0.6%) patients. Residual mild AR was
observed in 89 MCV patients (19.6%) versus 37 ESV
patients (10.9%); moderate AR occurred in 8 MCV patients
(1.8%) versus 5 ESV patients (1.5%),and severe AR in 1
MCV patient (0.2%) versus 1 ESV patient (0.3%). Figure 1
illustrates the impact of AR on unadjusted survival. The
device was successful in 424 MCV patients (93.6%) and in
327 ESV patients (96.2%).
Major vascular complications and life-threatening bleeding
occurred, respectively, in 41 (9.1%) and 53 (11.7%) of MCV
patients versus 50 (14.7%) and 48 (14.1%) ESV patients. At 1
year, 79 patients (17.4%) in the MCV group died versus 46
(13.6%) in the ESV group; 42 (9.3%) versus 26 (7.6%),
respectively, were cardiac deaths. Figure 2 illustrates unad-
justed survival curves in the overall population.
Propensity-matched analysis. After propensity-score
matching was performed, there were 204 matched pairs of
patients in each group. Baseline characteristics of the
matched groups are shown in Table 2. In the propensity
model, because sheath size was a dichotomous variable, only
newer generation devices were included.
VARC outcomes for the matched groups. No differences
were observed between MCV and ESV patients in the
occurrence of 30-day all-cause (MCV, 8.8% vs. ESV, 6.4%;
HR: 1.422; 95% CI: 0.677 to 2.984; p  0.352) or
cardiovascular (MCV, 6.9% vs. ESV, 6.4%; HR: 1.083; 95%
CI: 0.496 to 2.364; p  0.842) mortality. In addition, there
were no statistically significant differences in spontaneous
MI (MCV, 0.5% vs. ESV, 1.5%; HR: 0.330; 95% CI: 0.034
to 3.200; p  0.339) or stroke (MCV, 2.9% vs. ESV, 1.0%;
R: 3.061; 95% CI: 0.610 to 15.346; p  0.174) (Table 3).
to AR
rade of aortic
red line moderate/severe AR.ding
the g
nd the
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February 26, 2013:830–6 SAPIEN Versus CoreValveFurthermore, there were no differences in major vascular
complications (MCV, 9.3% vs. ESV, 12.3%; HR: 0.735; 95%
CI: 0.391 to 1.382; p  0.340) or life-threatening bleeding
(MCV, 13.7% vs. ESV, 8.8%; HR: 1.644; 95% CI: 0.878 to
3.077; p  0.120). Consequently, no difference was observed
in 30-day VARC combined safety (MCV, 26.5% vs. ESV,
23.0%; HR: 1.203; 95% CI: 0.766 to 1.887; p  0.422).
Figure 2 Freedom from All-Cause and Cardiac Mortality at the
Freedom from all-cause (A) and cardiovascular mortality (B) at 1 year in the unad
and the blue line the Edwards SAPIEN/SAPIEN XT transcatheter heart valve (ESV).
Baseline Characteristics ofthe Propensity-Matched PopulationTable 2 B seline Characteristics ofthe Propensity-Matched Population
MCV (n  204) ESV (n  204) p Value
Age, yrs 82.1 6.0 81.8 7.8 0.656
Male 92 (45.1) 100 (49.0) 0.427
NYHA functional class III/IV 169 (82.8) 163 (80.3) 0.507
Logistic EuroSCORE, % 22.1 12.2 21.7 13.7 0.778
STS score, % 9.3 7.2 8.9 7.0 0.538
Previous stroke 25 (12.3) 24 (11.8) 0.879
Previous MI 19 (9.3) 22 (10.8) 0.621
Previous CABG 27 (13.2) 31 (15.2) 0.571
Previous PCI 69 (33.8) 63 (30.9) 0.525
Diabetes mellitus 58 (28.4) 56 (27.5) 0.825
Hypertension 154 (75.5) 145 (71.1) 0.314
GFR 60 ml/min 128 (62.7) 123 (60.3) 0.611
COPD 58 (28.4) 59 (28.9) 0.913
PVD 47 (23.0) 41 (20.0) 0.470
Annulus, mm 22.7 2.3 22.9 1.8 0.417
AVA, mm2 0.7 0.2 0.7 0.2 0.250
LVEF 35% 29 (14.2) 32 (15.7) 0.677Values are n (%) or mean  SD.
Abbreviations as in Table 1.Conversely, as expected, there was less need for a PPM
after treatment with an ESV (MCV, 22.5% vs. ESV, 5.9%;
HR: 4.634; 95% CI: 2.373 to 9.050; p  0.001).
No significant differences were found in residual mod-
erate/severe AR (MCV, 1.5% vs. ESV, 0.5%; HR: 3.015;
95% CI: 0.311 to 29.243; p  0.341) or indeed residual
mild AR (MCV, 17.3% vs. ESV, 11.7%; HR: 1.569; 95%
CI: 0.887 to 2.776; p  0.122). Supplementary Online
Table 3 illustrates the degree of residual AR. Further-
more, there was no difference in the aortic valve area after
the procedure (1.77  0.41 mm Hg vs. 1.71  0.32 mm
Hg; HR: 1.525; 95% CI: 0.752 to 3.092; p  0.242).
Notably, there was no significant increased need for a
second valve (MCV, 2.9% vs. ESV, 1.0%; HR: 3.061;
95% CI: 0.610 to 15.346; p  0.174) with MCV despite
11 patients (5.4%) versus no patients (p  0.001)
undergoing embolization. However, this was not re-
flected in device success, which was similar between
groups (MCV, 95.6% vs. ESV, 96.6%; HR: 0.770; 95%
CI: 0.281 to 2.108; p  0.611).
At 1 year, there were no differences in all-cause (MCV,
16.2% vs. ESV, 12.3%; HR: 1.374; 95% CI: 0.785 to
2.407; p  0.266) or cardiovascular mortality (MCV,
8.3% vs. ESV, 7.4%; HR: 1.145; 95% CI: 0.556 to 2.361;
p  0.713). No difference was also observed in the
combined efficacy endpoint (MCV, 32.4% vs. ESV,
25.6%; HR: 1.389; 95% CI: 0.903 to 2.136; p  0.135).
justed Analysis
analysis. The green line represents the Medtronic CoreValve (MCV)Unad
justedKaplan-Meier survival curves are shown in Figure 3.
ademic
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The main findings of our study are as follows. 1) There were
no differences in 30-day or 1-year mortality between MCV
and ESV; 2) moreover, there were no differences in combined
VARC Outcomes in the Propensity-Matched PopTable 3 VARC Outcomes in the Propensity-M
Outcome
No. (%) of E
MCV (n  204)
30 days
All-cause mortality 18 (8.8)
Cardiac mortality 14 (6.9)
Spontaneous MI 1 (0.5)
Major stroke 6 (2.9)
Major vascular 19 (9.3)
Life-threatening bleeding 28 (13.7)
Major bleeding 37 (18.1)
Acute kidney injury stage 3 8 (3.9)
Device success 195 (95.6)
Combined safety 54 (26.5)
1 Year
All-cause mortality 33 (16.2)
Cardiac mortality 17 (8.3)
NYHA functional class III/IV 23 (14.5)
Rehospitalization 22 (18.8)
Mean gradient, mm Hg 10.1 5.4
Moderate-severe AR 8 (5.2)
Combined efficacy 66 (32.4)
AR  aortic regurgitation; CI  confidence interval; VARC  Valve Ac
Figure 3 Freedom From All-Cause and Cardiac Mortality at the
Freedom from all-cause (A) and cardiovascular (B) mortality in the propensity-mat
The green line represents MCV and the blue line the ESV. Abbreviations as in Figusafety and efficacy endpoints between valves; 3) as expected,
there was a greater need for PPM after MCV implantation.
TAVI is now an acceptable treatment option for those
deemed at high risk of surgical aortic valve replacement.
There are currently 2 commercially available devices avail-
oned Population
HR 95% CI p Valuen  204)
(6.4) 1.422 0.677–2.984 0.352
(6.4) 1.083 0.496–2.364 0.842
(1.5) 0.330 0.034–3.200 0.339
(1.0) 3.061 0.610–15.346 0.174
(12.3) 0.735 0.391–1.382 0.340
(8.8) 1.644 0.878–3.077 0.120
(22.1) 0.783 0.481–1.273 0.324
(3.4) 1.155 0.411–3.245 0.785
(96.6) 0.770 0.281–2.108 0.611
(23.0) 1.203 0.766–1.887 0.422
(12.3) 1.374 0.785–2.407 0.266
(7.4) 1.145 0.556–2.361 0.713
(9.1) 1.691 0.848–3.374 0.136
(13.2) 1.520 0.803–2.879 0.198
3 4.0 0.991 0.938–1.047 0.738
(2.8) 1.905 0.561–6.467 0.302
(25.6) 1.389 0.903–2.136 0.135
Research Consortium; other abbreviations as in Table 1.
ensity-Matched Analysis
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February 26, 2013:830–6 SAPIEN Versus CoreValveable for TF: MCV and ESV. A number of studies have
provided a comparison, including the FRANCE 2 (French
Aortic National CoreValve and Edwards) registry (8) and
the U.K. TAVI (United Kingdom Transcatheter Aortic
Valve Implantation) registry (7). In addition, it is important
to understand that these registries report only unadjusted
analyses and do not take into account the significant
differences at baseline.
In our series, the adjusted all-cause mortality at 30 days
(MCV, 8.8% vs. ESV, 6.4%) is similar to the unadjusted
all-cause mortality reported in the FRANCE 2 (8) and the
U.K. TAVI registries (7). It is also comparable with that
reported by several initial registries, varying from 0.9% to
11.0% for ESV and 6.0% to 15.2% for MCV via transfemo-
ral approach (1,13,14). Furthermore, at 1 year, there re-
mained no differences in all-cause mortality between valves
(MCV, 16.3% vs. ESV, 13.9%), which was favorable com-
pared with other studies (7,8). No difference was also
observed at 1 year in the combined efficacy endpoint.
Importantly, there was no difference in major vascular
complications after matching for sheath size (MCV, 9.3%
vs. ESV, 12.3%). It was previously demonstrated that major
vascular complications were improved with the introduction
of the newer device (15). Nevertheless, the introduction of
smaller sheaths is warranted to reduce complications fur-
ther. The introduction of the Edwards SAPIEN 3 will
reduce the sheath size to 14/16-F, with similar improve-
ments expected with the MCV.
In our series, the 2.6% incidence of stroke seems accept-
able compared with previous experience (1.2% to 5.0%)
(3,5,6–8,16). Of note, patients who had a stroke more
frequently had valve embolization or needed a second valve.
At the center with the highest rate of stroke, the rate of
embolization was 10.4%. It is possible that the process of
recapturing and the subsequent retrieval of the valve and
delivery system through the aorta could have played a role.
As previously reported (7,16), there was a greater need for
PPM with the MCV, likely related to valve structure and
design.
The U.K. TAVI registry demonstrated in the comparison
between valve types (unadjusted) an increased risk of mod-
erate/severe AR with the MCV (MCV, 17.3% vs. ESV,
9.6%; p  0.001) (7). Importantly, in our study in both
unadjusted and adjusted analyses, no differences were ob-
served in the incidence of residual AR of any grade between
valve types. In addition, our data confirm that moderate/
severe AR is associated with increased 1-year mortality.
There is growing evidence in the current literature that
moderate/severe AR is correlated with higher mortality
(8,17–19). Notably, the presence of residual AR in our study
significantly affected both all-cause and cardiac mortality
(Fig. 1). In fact, the freedom from all-cause and cardiac
mortality was significantly lower with moderate/severe AR
compared with nil/trivial or mild AR.
The presence of residual AR is one of the limitations of
the currently available TAVI devices, and paravalvular leaksneed to be decreased to improve outcomes further. In
addition, facilitation of accurate positioning, device re-
trieval, and reduction of the delivery catheter diameter will
continue to improve outcomes. Overall, our results are
encouraging, showing no difference between commercially
available valve types except for a greater need for a PPM
with the MCV, but clearly longer term follow-up in the
setting of an adequately powered randomized clinical trial is
needed.
Study limitations. Due to the nonrandomized and retro-
spective nature of this study, the findings are subject to
selection bias and confounding with regard to the pre-
procedural risk of the patient. In an aim to minimize these
biases, propensity-score matching was performed; however,
hidden bias may remain due to the influences of unmea-
sured confounders.
The lack of a central core laboratory and adjudication
committee means potential reporting bias and is a further
limitation. Finally, the clinical follow-up duration limits
conclusions on valve durability.
Conclusions
No differences between the 2 commercially available TF
TAVI devices were observed in the adjusted analysis in the
study population in VARC outcomes at 30 days and 1 year,
except for the need for a PPM with the MCV. These results
need to be confirmed in a randomized trial.
Reprint requests and correspondence: Dr. Antonio Colombo,
Interventional Cardiology Unit, San Raffaele Scientific Institute,
Via Olgettina 60, 20132 Milan, Italy. E-mail: colombo.
antonio@hsr.it.
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